
Dylan Stavish
Articles
-
Jul 3, 2024 |
cell.com | Dylan Stavish |Christopher Price |Gabriele Gelezauskaite |Haneen Sohail Alsehli
Highlights•Increase in chromosome 1q gains in recent years is linked to feeder-free cultures•Feeder-free conditions (E8/vitronectin) confer high levels of genome damage on hPSC•Amplification of MDM4 on chromosome 1q alleviates genome damage-induced apoptosis•Karyotypically abnormal cells have a context-dependent selective advantageSummaryCulture-acquired variants in human pluripotent stem cells (hPSCs) hinder their applications in research and clinic.
-
Jul 3, 2024 |
biorxiv.org | Selcan Aydin |Daniel A Skelly |Dylan Stavish |Alexander Stanton
AbstractThe genetic integrity of pluripotent stem cells (PSC) is integral to their applications in research and therapy, but it is compromised by frequent development of copy number variations. Little is known about the basis of the variable genomic integrity among different PSC lines. Here we identify aneuploidies using RNA-seq and proteomics data from a panel of mouse embryonic stem cell (mESC) lines derived from 170 Diversity Outbred mice.
-
Dec 13, 2023 |
biorxiv.org | Christopher Price |Dylan Stavish |Owen Laing |Theodore Wing
AbstractHuman pluripotent stem cell (hPSC)-derived cardiomyocytes have emerged as powerful tools for disease modelling and cell therapy. The production of cardiomyocytes from hPSCs typically requires expanding large numbers of hPSCs and maintaining them in culture for extended periods of time. This in turn predisposes hPSCs to the acquisition of non-random genetic changes, including recurrent gains of chromosome 1q.
-
Sep 21, 2023 |
biorxiv.org | Dylan Stavish |Christopher Price |Gabriele Gelezauskaite |Kimberly A. Leonhard
AbstractSince the first derivation of human pluripotent stem cells (hPSCs), the number of culture conditions has steadily increased, making hPSC culture more facile. Nonetheless, there remains the persistent issue of culture-acquired genetic changes, hampering the reproducibility of hPSC research and jeopardising their clinical use.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →